FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

GRANULES Share Price Discussion

Granules India Ltd.
NSE: GRANULES | BSE: 532482 | ISIN: INE101D01020 | Sector: Pharmaceuticals and health care

GRANULES Rating

4.9/5 (8 Ratings)
GRANULES Share Price *
184.35 -3.6 (-1.92%)
* (quote may be delayed)
Find answers to all your questions on live GRANULES message board: Is GRANULES buy or sell? Should I buy GRANULES shares? Why are GRANULES shares falling? Should I invest in GRANULES stock?

You can also check GRANULES share price target recommended by brokerages.

GRANULES Discussion Forum

@tradingbud • Reputation: 0

GRANULES - chart - 617447
#granules can be added on dips till 160 and on the upper side it seems 210/230/250 🙂
Like
reply
Reply
@guptan • Reputation: 3,172

GRANULES - chart - 613709
GRANULES
1
reply
Reply

BUY GRANULES INDIA CMP 188
ONLY NEAR 160 - 140 START
SUPPORT - 120
TARGET - 240 250 260 ++
Like
reply
Reply

GRANULES - chart - 613341
BUY GRANULES INDIA CMP 188
ONLY NEAR 140 - 160 START ACCUMULATING
SUPPORT - 120
TARGET - 250 250 260 ++
Like
reply
Reply

Granules India received two observations following completion of the USFDA inspection in Hyderabad unit.
Like
reply
Reply
ICHIMOKU CHARTS in GRANULES

#granules call given at 127 now at 170 plus . 200 coming soon #ichimoku
Like
reply
Reply

GRANULES - chart - 604902
#granules call given at 127 now at 170 plus . 200 coming soon #ichimoku
Like
reply
Reply
GRANULES

Type
Buy
Instrument
GRANULES
Entry Price
₹178.75
Price@Trade
₹178.75
Target Price
₹181
Stop Price
₹177
Valid Till
Feb 14, 2020 3:20 PM
Margin
₹178.75 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹177
Net P&L
-0.98% Loss
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Feb 14 7:12 PM

Update
Stoploss Hit
Exit Price
₹177
@ansarshaikh • Reputation: -1,361

Target achieved of 169
Like
reply
Reply
@newsbot • Reputation: 2,308
Granules India gets tentative nod from USFDA for expectorant tablets
"US Food & Drug Administration (USFDA) has tentatively approved its Abbreviated New Drug Application for Guaifenesin extended-release tablets, 600 mg and 1200 mg (OTC)," the company said in a filing to the BSE.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Granules India gets tentative nod from USFDA for generic Colchicine capsules
The US Food and Drug Administration (USFDA) has tentatively approved the abbreviated new drug application (ANDA) filed by Granules Pharmaceuticals Inc for Colchicine capsules in the strength of 0.6 mg, Granules India said in a filing to the BSE.
Moneycontrol
Like
reply
Reply

GRANULES - chart - 587885
#granules weekly breakout confirmed 165
200 is possible
( self invested in from very lower levels so dont jump blindly #ichimoku #chartsdontlie
Like
reply
Reply
@100billionclub • Reputation: 3,727
GRANULES

Type
Buy
Instrument
GRANULES
Entry Price
₹165.5
Price@Trade
₹165.3
Target Price
₹174
Stop Price
₹159.9
Valid Till
Feb 14, 2020 3:20 PM
Margin
₹165.5 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹159.9
Net P&L
-3.38% Loss
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Feb 7 3:55 PM

Update
Trade Entered
Entry Price
₹165.5
TrackerBot @trackerbot
Feb 10 2:47 PM

Update
Stoploss Hit
Exit Price
₹159.9
@ansarshaikh • Reputation: -1,361

Short term buy call tgt 169
Like
reply
Reply
@newsbot • Reputation: 2,308
Granules Pharmaceuticals, Inc gets USFDA nod for Colchicine tablets
Familial mediterranean fever is a genetic disorder that causes recurrent episodes of fever that are typically accompanied by pain in the abdomen, chest, or joints.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Granules India hits 52-week high after USFDA approval
Colchicine tablets are used in the treatment of Familial Mediterranean Fever.
Moneycontrol
Like
reply
Reply
ICHIMOKU CHARTS in GRANULES
GRANULES
Trade entered: Buy GRANULES @157.25 Target@200 ...

Granules bought at 157 now 161
Weekly chart breakout on ichimoku
Target 200
Like
reply
Reply
@newsbot • Reputation: 2,308
Granules India share price jumps 5% on USFDA nod for antiviral medicine
Domestic brokerage firm Sharekhan by BNP Paribas has maintained a positive view on the stock with an upside potential of 12-15 percent while Anand Rathi Share has a buy recommendation with a target price of Rs 181.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Granules India arm gets USFDA nod for Valganciclovir hydrochloride oral solution
"The US Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc, a-wholly owned foreign subsidiary of Granules India Ltd for Valganciclovir hydrochloride for oral solution, 50 mg/ml," the company said in a regulatory filing.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Granules India divests entire stake in Granules-Biocause Pharmaceutical
Last year, Granules India had intimated about the divestment of the entire stake of the JV company for a total consideration of RMB 109 million (around Rs 110.8 crore).
Moneycontrol
Like
reply
Reply
@databot • Reputation: 2,050

Geojit Financial Services target on GRANULES
Date: 04-Feb-20 Broker: Geojit Financial Services Price @ Call: 146.4 Target: 175 Recommendation: BUY
Like
reply
Reply
@ygtrader • Reputation: 1,722

Granules is Recommended to Buy,
Prices broke a long term trendline with high volume,
And prices are ready to make new historical highs,
Buy on dips.
(Every price dip is buying opportunity)
Like
reply
Reply
@newsbot • Reputation: 2,308
Q3 earnings mixed so far; brokerages maintain 'buy' on 10 stocks with 9-23% upside
Last week, FIIs bought equities worth Rs 1,790.6 crore, while Domestic Institutional Investors sold equities worth of Rs 2,620.48 crore
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Small & midcaps back in spotlight as FIIs raise stake in 122 BSE companies
Most of the companies in which FIIs raised stake are financially sound, have prudent management but be selective while picking stocks, experts say.
Moneycontrol
Like
reply
Reply

GRANULES - 552801
LTP 159.80, gain of 9.45% in a day
2
reply
Reply
@databot • Reputation: 2,050

Centrum target on GRANULES
Date: 21-Jan-20 Broker: Centrum Price @ Call: 146.96 Target: 205 Recommendation: BUY
Like
reply
Reply
@pritpatel • Reputation: 3,508
GRANULES

Type
Buy
Instrument
GRANULES
Entry Price
₹158.9
Price@Trade
₹158.55
Target Price
₹170
Stop Price
₹148
Valid Till
Jan 24, 2020 3:20 PM  Jan 29, 2020 3:20 PM
Margin
₹158.9 approx for 1 Qty
Status
Validity Over
Exit Price
₹153.6
Net P&L
-3.34% Loss
Like
reply
Reply (3)
Latest replies
TrackerBot @trackerbot
Jan 23 8:41 PM

Update
Trade Entered
Entry Price
₹158.9
PRIT PATEL @pritpatel
Jan 24 3:12 PM

Update
Time Extended
Price @ Update
₹156.2
Original Time
Jan 24, 2020 3:20 PM
New Time
Jan 29, 2020 3:20 PM
TrackerBot @trackerbot
Jan 29 8:50 PM

Update
Validity Over
Exit Price
₹153.6
Net P&L
-3.34% Loss
GRANULES

Type
Buy
Instrument
GRANULES
Entry Price
₹157.25
Price@Trade
₹157.25
Target Price
₹200
Stop Price
₹125
Valid Till
Jan 22, 2021 3:20 PM
Margin
₹157.25 approx for 1 Qty
Status
Exited
Exit Price
₹187.4
Net P&L
19.17% Profit
One year target
Like
reply
Reply (3)
Latest replies
Green Bulls 786 @green
Jan 23 7:59 PM

Sir it looks it will reach in 1 week

Update
Exited
Exit Price
₹187.4
Net P&L
19.17% Profit
@guptan • Reputation: 3,172

GRANULES - chart - 551855
GRANULES
Like
reply
Reply (2)
Latest replies
Green Bulls 786 @green
Jan 23 6:38 PM

How many days target will reach sir

Weekly some weeks
@databot • Reputation: 2,050

AnandRathi target on GRANULES
Date: 21-Jan-20 Broker: AnandRathi Price @ Call: 146.96 Target: 181 Recommendation: BUY
Like
reply
Reply
@databot • Reputation: 2,050

Motilal Oswal target on GRANULES
Date: 22-Jan-20 Broker: Motilal Oswal Price @ Call: 139.65 Target: 165 Recommendation: BUY
Like
reply
Reply

Granules India today announced an interim dividend of Rs0.25 per share. The ex dividend date is Thursday, January 30 and the record date is Friday, January 31, 2020.
1
reply
Reply
@TTA • Reputation: 23,829
GRANULES

Type
Buy
Instrument
GRANULES
Entry Price
₹147.6
Price@Trade
₹147.6
Target Price
₹164.9
Stop Price
₹137.9
Valid Till
Feb 20, 2020 3:20 PM
Margin
₹147.6 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹137.9
Net P&L
-6.57% Loss
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Feb 1 8:55 PM

Update
Stoploss Hit
Exit Price
₹137.9

GRANULES INDIA LTD Q3 FY 20.pdf
2 MB
GRANULES INDIA QUARTERLY PRESENTATION
1
reply
Reply

Granules India’s Q3 FY20 profit increased 6.1% y/y to Rs 64 crore, while revenue was up 11.4% y/y to Rs 704 crore. The margin expanded 390bps y/y to 21.8%. Also, the board approved share buyback of up to 1.25 crore equity share at Rs 200 per share. The stock closed 5% lower.
Like
reply
Reply
@TTA • Reputation: 23,829

Granules India – Q3 FY20 (Unaudited - Cons)
Share price – 146
Revenue from operations at 703.95 Cr
631.77 Cr (11.82%) YoY | 699.55 Cr (0.55%) QoQ
YTD 9 months ended revenue: 1,999 Cr Vs. 1,666 Cr (19.97%)
Net Profit of 64.02 Cr
60.31 Cr (6.66%) YoY 95.79 (-32.57%) ...
Read more...
Like
reply
Reply
@mayurpatel • Reputation: 16,057
TREAD WITH TREND in GRANULES
GRANULES
Trade entered: Sell GRANULES @150.45 Target@140...

HIT 140------------------------
1
reply
Reply
@vijayjaria • Reputation: -7,514

#JustIn | Granules India board approves share buyback of up to 1.25 cr equity shares worth Rs 250 cr at Rs 200/sh
Like
reply
Reply
@mayurpatel • Reputation: 16,057
GRANULES

Type
Sell
Instrument
GRANULES
Entry Price
₹150.45
Price@Trade
₹150.45
Target Price
₹140
Stop Price
₹160
Valid Till
Jan 28, 2020 3:20 PM
Margin
₹150.45 approx for 1 Qty
Status
Exited
Exit Price
₹145.4
Net P&L
3.36% Profit
Like
reply
Reply (1)
Latest replies
TRADE WITH TREND @mayurpatel
Jan 21 7:50 PM

Update
Exited
Exit Price
₹145.4
Net P&L
3.36% Profit

BRIEF-Granules India Says US FDA Issues 3 Observations To Unit's Facility - Reuters
20-Jan-2020 03:03:46 PM
Jan 20 (Reuters) - Granules India Ltd GRAN.NS:
US FDA HAS COMPLETED INSPECTION OF THE FACILITY OF GRANULES PHARMACEUTICALS, INC.
US FDA HAS COMPLETED INSPECTION WITH THREE ...
Read more...
1
reply
Reply

💠💠
YOUR FREE EQUITY CASH CALL FOR THIS FORUM TODAY:
BUY GRANULS AT THE VERY BEGINING
STRICT STOP LOSS - 143
1ST TARGET - 146.20
2ND TARGET - 147
3RD TARGET - 147.75
## GO WITH SAFER QUANTITY ##
Disclaimer: All my Views/Suggestions/Calls are for Education Purpose Only. Please co...
Read more...
Like
reply
Reply
HALAL INVESTMENT in GRANULES
GRANULES 91 TO 131+ IF HV HOLD FOR 138/145+

GRANULES 146.50
HOLD ON
Like
reply
Reply
Karvy CMD Parthasarathy resigns as Independent Director of Granules India Board
C Parthasarathy, Chairman and Managing Director of the Hyderabad-based Karvy Group, has
article wn
2
reply
Reply
@invictotrader • Reputation: 2,665

Granules India receives US FDA's ANDA approval for Loratadine Tablets
Like
reply
Reply
@TTA • Reputation: 23,829

GRANULES: CO RECEIVED USFDA APPROVAL FOR ANDA
1
reply
Reply
@invictotrader • Reputation: 2,665

Granules India share price rises 1% on stake sale in Chinese JV The conclusion of the transaction is subject to the fulfillment of certain closing conditions and regulatory approvals.
Like
reply
Reply

Granules India formed an agreement with Hubei Biocause Heilen Pharmaceutical company to sell 3.3 crore equity shares worth RMB 109M held by its joint venture partner, Granules-Biocause Pharmaceutical Co. Limited.
1
reply
Reply

GRANULES INDIA LTD - FDA MADE TWO OBSERVATIONS
Like
reply
Reply
@guptan • Reputation: 3,172

GRANULES - chart - 446185
GRANULES
Like
reply
Reply
  • GRANULES - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization2,905.51
    Enterprise Value3,776.07
    Price to Earnings18.9
    Price to Book Value2.04
    Return on Capital Employed0.11
    Return on Equity0.11
    Face Value1
    Dividend Yield0.01
  • GRANULES Share Price - Technicals

    keyboard_arrow_down
    GRANULES - 52 Week High₹189
    GRANULES - 52 Week Low₹84
  • GRANULES - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    4-Feb-20Geojit Financial ServicesBuy175
    22-Jan-20Motilal OswalBuy165
    21-Jan-20AnandRathiBuy181
    21-Jan-20CentrumBuy205
    7-Nov-19Axis DirectBuy144
    GRANULES Brokerage Price Target
  • GRANULES Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Feb 20187.65188.45182184.35
    Feb 19181189180.5187.95
    Feb 18173.65180.5172.5179
    Feb 17175179.7173.05175.15
    Feb 14170.9179.5168.1175.6
  • GRANULES Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹161.22
    30 Day Moving Average₹154.53
    50 Day Moving Average₹143.18
    100 Day Moving Average₹130.69
    200 Day Moving Average₹114.91
  • GRANULES - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue1,6471,349.480.22
    Operating Profit294295.8-0.01
    Profit Before Tax208206.80.01
    Net Income139142.83-0.03
  • GRANULES - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds1,4231,2780.11
    Total Liabilities1,4011,3400.05
    Total Assets2,8242,6180.08
  • GRANULES - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity24197.22-0.88
    Cash from Investing Activity-495-292.750.69
    Cash from Financing Activity52924.220.86
    Net Cash Flow58-71.34-1.81
  • GRANULES - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.050.08
    Return on Equity0.110.16
    Return on Capital Employed0.110.16
  • GRANULES - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.36
    3 Year CAGR Growth in Operating Profit0.4
    3 Year CAGR Growth in EBIDTA0.49
    3 Year CAGR Growth in Net Income0.46
    3 Yr CAGR Growth - Diluted EPS0.18
  • GRANULES - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue1.42
    5 Year CAGR Growth in Operating Profit2.72
    5 Year CAGR Growth in EBIDTA2.92
    5 Year CAGR Growth in Net Income3.61
    3 Yr CAGR Growth - Diluted EPS-0.63
  • GRANULES - Recent News

    keyboard_arrow_down
    NewsBot
    Feb 13 6:08 PM
    Granules India gets tentative nod from USFDA for expectorant tablets
    Moneycontrol
    NewsBot
    Feb 11 9:28 PM
    Granules India gets tentative nod from USFDA for generic Colchicine capsules
    Moneycontrol
    NewsBot
    Feb 6 4:33 PM
    Granules Pharmaceuticals, Inc gets USFDA nod for Colchicine tablets
    Moneycontrol
    NewsBot
    Feb 6 3:43 PM
    Granules India hits 52-week high after USFDA approval
    Moneycontrol
    NewsBot
    Feb 5 4:43 PM
    Granules India share price jumps 5% on USFDA nod for antiviral medicine
    Moneycontrol
    NewsBot
    Feb 5 4:23 PM
    Granules India arm gets USFDA nod for Valganciclovir hydrochloride oral solution
    Moneycontrol
    NewsBot
    Feb 4 5:28 PM
    Granules India divests entire stake in Granules-Biocause Pharmaceutical
    Moneycontrol
    NewsBot
    Jan 28 7:33 PM
    Q3 earnings mixed so far; brokerages maintain 'buy' on 10 stocks with 9-23% upside
    Moneycontrol
    NewsBot
    Jan 28 3:23 PM
    Small & midcaps back in spotlight as FIIs raise stake in 122 BSE companies
    Moneycontrol
    NewsBot
    Oct 22 6:58 PM
    Granules India zooms 14% after Q2 profit of Rs 96 cr, USFDA nod for allergy drug
    Moneycontrol
  • GRANULES - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. S...
    Aurobindo Pharma Ltd. Sector: Pharma...
    Biocon Ltd. Sector: Pharmaceuticals ...
    Cipla Ltd. Sector: Pharmaceuticals a...
    Dr. Reddy's Laboratories Ltd. Sector...
    Lupin Ltd. Sector: Pharmaceuticals an...
    Piramal Enterprises Ltd. Sector: Phar...
    Divi's Laboratories Ltd. Sector: Pha...
    Glenmark Pharmaceuticals Ltd. Sector...
    Strides Pharma Science Ltd. Sector: P...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.